Skip to main content

Sean J. Mulvihill, MD

Languages spoken: English

Academic Information

Departments: Surgery - Professor Emeritus

Divisions: General Surgery

Academic Office Information

Research Interests

  • Pancreatic Cancer
  • Clinical Trials in Pancreatic Disease
  • Quality of Health Care
  • Education, Professional, Retraining
  • Gastrointestinal Physiology
Sean Mulvihill, MD has specialized expertise in the treatment of diseases of the liver, biliary tract, and pancreas. He is board certified in general surgery. His main clinical focus is in the management of patients with pancreatic tumors, such as pancreatic adenocarcinoma and neuroendocrine tumors. He has integrated a research program funded by the National Cancer Institute into his clinical practice, with the aim of determining the underlying cause of these cancers and identifying new treatment approaches. This knowledge is leading to improved diagnostic strategies, improved selection of treatment options, and improved outcomes.

Education History

Chief Resident University of California - Los Angeles
General Surgery
Chief Resident
Residency University of California - Los Angeles
General Surgery
Postdoctoral Fellowship University of California - Los Angeles
GI Research
Postdoctoral Fellow
Residency University of California - Los Angeles
General Surgery
Internship University of California - Los Angeles
Professional Medical University of Southern California
Undergraduate University of California - Davis

Selected Publications

  1. Swords DS, Mulvihill SJ, Brooke BS, Stoddard GJ, Firpo MA, Scaife CL (2019). County-level Variation in Use of Surgery and Cancer-specific Survival for Stage I-II Pancreatic Adenocarcinoma. Ann Surg, 272(6), 1102-1109.
  2. Stokes SM, Scaife CL, Brooke BS, Glasgow RE, Mulvihill SJ, Finlayson SRG, Varghese TK Jr (2020). Hospital Costs Following Surgical Complications: A Value-driven Outcomes Analysis of Cost Savings Due to Complication Prevention. Ann Surg, 275, e375-e381.
  3. Swords DS, Mulvihill SJ, Brooke BS, Firpo MA, Scaife CL (2019). Size and Importance of Socioeconomic Status-Based Disparities in Use of Surgery in Nonadvanced Stage Gastrointestinal Cancers. Ann Surg Oncol, 27(2), 333-341.
  4. Swords DS, Francis SR, Lloyd S, Garrido-Laguna I, Mulvihill SJ, Gruhl JD, Christensen MC, Stoddard GJ, Firpo MA, Scaife CL (2018). Lymph Node Ratio in Pancreatic Adenocarcinoma After Preoperative Chemotherapy vs. Preoperative Chemoradiation and Its Utility in Decisions About Postoperative Chemotherapy. J Gastrointest Surg, 23(7), 1401-1413.
  5. Bleicher J, Lombardo S, Carbine S, Kapitonov D, Pletneva MA, Mulvihill SJ (2019). Adrenocorticotropin Hormone Secreting Carcinoma of the Pancreas: A Case Report. J Pancreat Cancer, 5(1), 22-25.
  6. Swords DS, Mulvihill SJ, Brooke BS, Skarda DE, Firpo MA, Scaife CL (2018). Disparities in utilization of treatment for clinical stage I-II pancreatic adenocarcinoma by area socioeconomic status and race/ethnicity. Surgery, 165(4), 751-759.
  7. Capello M, Vykoukal JV, Katayama H, Bantis LE, Wang H, Kundnani DL, Aguilar-Bonavides C, Aguilar M, Tripathi SC, Dhillon DS, Momin AA, Peters H, Katz MH, Alvarez H, Bernard V, Ferri-Borgogno S, Brand R, Adler DG, Firpo MA, Mulvihill SJ, Molldrem JJ, Feng Z, Taguchi A, Maitra A, Hanash SM (2019). Exosomes harbor B cell targets in pancreatic adenocarcinoma and exert decoy function against complement-mediated cytotoxicity. Nat Commun, 10(1), 254.
  8. Swords DS, Mulvihill SJ, Skarda DE, Finlayson SRG, Stoddard GJ, Ott MJ, Firpo MA, Scaife CL (2017). Hospital-level Variation in Utilization of Surgery for Clinical Stage I-II Pancreatic Adenocarcinoma. Ann Surg, 269(1), 133-142.
  9. Sharib JM, Fonseca AL, Swords DS, Jaradeh K, Bracci PM, Firpo MA, Hatcher S, Scaife CL, Wang H, Kim GE, Mulvihill SJ, Maitra A, Koay EJ, Kirkwood KS (2018). Surgical overtreatment of pancreatic intraductal papillary mucinous neoplasms: Do the 2017 International Consensus Guidelines improve clinical decision making? Surgery, 164(6), 1178-1184.
  10. Swords DS, Mulvihill SJ, Firpo MA, Scaife CL (2018). Causes of Death and Conditional Survival Estimates of Medium- and Long-term Survivors of Pancreatic Adenocarcinoma. JAMA Oncol, 4(8), 1129-1130.
  11. Young EL, Thompson BA, Neklason DW, Firpo MA, Werner T, Bell R, Berger J, Fraser A, Gammon A, Koptiuch C, Kohlmann WK, Neumayer L, Goldgar DE, Mulvihill SJ, Cannon-Albright LA, Tavtigian SV (2018). Pancreatic cancer as a sentinel for hereditary cancer predisposition. BMC Cancer, 18(1), 697.
  12. Swords DS, Zhang C, Presson AP, Firpo MA, Mulvihill SJ, Scaife CL (2017). Association of time-to-surgery with outcomes in clinical stage I-II pancreatic adenocarcinoma treated with upfront surgery. Surgery, 163(4), 753-760.
  13. Swords DS, Firpo MA, Johnson KM, Boucher KM, Scaife CL, Mulvihill SJ (2017). Implications of inaccurate clinical nodal staging in pancreatic adenocarcinoma. Surgery, 162(1), 104-111.
  14. Capello M, Bantis LE, Scelo G, Zhao Y, Li P, Dhillon DS, Patel NJ, Kundnani DL, Wang H, Abbruzzese JL, Maitra A, Tempero MA, Brand R, Firpo MA, Mulvihill SJ, Katz MH, Brennan P, Feng Z, Taguchi A, Hanash SM (2016). Sequential Validation of Blood-Based Protein Biomarker Candidates for Early-Stage Pancreatic Cancer. J Natl Cancer Inst, 109(4).
  15. Poruk KE, Firpo MA, Mulvihill SJ (2014). Screening for pancreatic cancer. Adv Surg, 48, 115-36.